Close
Translation of novel radiotracers in clinical studies requires an in-depth understanding of the compound’s binding profile at a molecular level.
With the aim to accelerate clinical applications of radiotracers, we use a translational imaging platform, combining nuclear tissue imaging techniques with in vivo positron emission tomography (PET) and single photon emission computed tomography (SPECT), to assess the suitability of radiotracers for a sought clinical purpose.
Tau PET tracers for imaging of the dementias
Imaging of the microtubule associated protein tau can potentially provide a surrogate outcome measure for clinical trials, and aid in early, as well as differential, diagnosis of dementias. However, the interpretation of clinical PET scans is challenging. With the aim to understand tracer binding at a molecular level, we assessed the binding profiles of tau tracers in human post mortem brain tissue.
To get an impression of our work please have a look at our video abstract.
References: Sander, Alzheimer & Dementia 2016 | Wren, Acta Neuropath Comm 2018 | Yap, Brain 2021
Imaging of multiple drug resistance
Multiple drug resistance (MDR) is a major clinical challenge for the successful treatment of many prevalent diseases of the central nervous system as well as cancers. In order to evaluate the role of the efflux transporters in the development of MDR and moreover, to provide diagnostic tools to quantify efflux pump activity in vivo, prodrug tracers for dynamic imaging with PET have been developed.
References: Galante, J Med Chem 2014 | Sander, J Med Chem 2015
